Cell Biotech Overview
- Founded
-
1995

- Status
-
Public
- Employees
-
123

- Stock Symbol
-
049960

- Share Price
-
$10.97
- (As of Wednesday Closing)
Cell Biotech General Information
Description
Cell Biotech Co Ltd is a specialized biotech company. It is engaged in the fermentation and coating technology development as well as manufacturing probiotics and lactic acid bacteria. The key product consists Probiotic DUOLAC, Nutra DUOLAC, LACTOClear, and LAB2PRO. The company distributes its products within domestic market and to overseas markets.
Contact Information
- 397, Aegibong-ro
- Wolgot-Myeon
- Gimpo, Gyeonggi 415-872
- South Korea
Cell Biotech Stock Performance
(As of Wednesday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$10.97 | $11.18 | $7.23 - $14.63 | $75.1M | 6.84M | 12.4K | $1.69 |
Cell Biotech Financials Summary
In Thousands, USD |
TTM 30-Sep-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
---|---|---|---|---|
EV | 8,393 | 64,110 | 103,253 | 68,026 |
Revenue | 39,072 | 40,922 | 38,606 | 39,414 |
EBITDA | 15,439 | 12,937 | 4,604 | 8,692 |
Net Income | 11,734 | 9,065 | 2,701 | 6,201 |
Total Assets | 83,071 | 94,853 | 96,525 | 93,498 |
Total Debt | 764 | 694 | 1,233 | 799 |
Cell Biotech Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Cell Biotech Patents
Cell Biotech Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
EP-3845632-A1 | Composition for promoting the growth of lactic acid bacteria comprising growth factors | Pending | 02-Jan-2020 | 00000000 | 0 |
US-20210207077-A1 | Composition for promoting the growth of lactic acid bacteria comprising growth factors | Pending | 02-Jan-2020 | 00000000 | 0 |
EP-3824743-A1 | Composition for preventing, relieving or treating climacteric disorders comprising lactic acid bacteria and isoflavone comprising soybean germ extract | Pending | 25-Nov-2019 | 000000000 | 0 |
US-20210204583-A1 | Composition for preventing, relieving or treating climacteric disorders comprising lactic acid bacteria and prebiotics | Pending | 25-Nov-2019 | 000000000 | 0 |
EP-3725161-A1 | Method of producing lactic acid bacteria dual-coated with protein and polysaccharide by using protein hydrolysate | Pending | 15-Apr-2019 | C12N1/20 |
Cell Biotech Executive Team (1)
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Myung-Jun Chung Ph.D | Chief Executive Officer |
Cell Biotech Board Members (1)
Name | Representing | Role | Since |
---|---|---|---|
00000 0000 | Cell Biotech | Board Member | 000 0000 |
Cell Biotech Signals
Cell Biotech Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Cell Biotech ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile

Pharmaceuticals
Industry
Rank
Percentile

Biotechnology
Subindustry
Rank
Percentile
